Brief Summary

This is an expanded access designed to provide access to Relatlimab for eligible participants.

Status
Available
EA Type
Individual Patients
Interventions

Drug: Relatlimab

Countries
Australia
Czechia
France
Singapore
United States
Locations

Local Institution
San Francisco, California, 94143

Available

Investigator: Site 0014

Local Institution
Tampa, Florida, 33612

Available

Investigator: Site 0013

Local Institution
Hays, Kansas, 67601

Available

Investigator: Site 0019

The Cancer Center At Hackensack University Medical Center
Hackensack, New Jersey, 07601

Available

Investigator: Michele Donato, Site 0001

Local Institution
Syracuse, New York, 13210

Available

Investigator: Site 0018

Local Institution
Charlottesville, Virginia, 22908

Available

Investigator: Site 0015

Inova Schar Cancer Institute
Fairfax, Virginia, 22031

Available

Investigator: Sekwon Jang, Site 0016
Contact: 571-472-0384

Contacts

Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:
Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Investigators

Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb

Sponsors / Collaborators
Bristol-Myers Squibb
NCT Number
NCT05170659